Is there a tirzepatide 80 mg dose — and what the highest licensed strength actually is

Where does the figure "80 mg" come from?

The short answer is: not from any legitimate UK source. Tirzepatide's licensed dose range in the UK runs from 2.5 mg to 15 mg per weekly injection, as set out in the medicine's Summary of Product Characteristics on the eMC. Those six steps are the only strengths Eli Lilly has manufactured for the UK market.

The 80 mg figure surfaces in a few ways. Some people confuse the total monthly quantity (four pens of 5 mg gives 20 mg across the month, for example) with a single-dose figure, but even that arithmetic does not reach 80. Others encounter it from overseas social-media sellers listing products by cumulative or compounded content. And occasionally it appears on counterfeit packaging, which does not have to follow any rules at all. The MHRA has warned publicly that fake pens have contained substances other than tirzepatide, including insulin, and that large seizures of counterfeit weight-loss products have taken place across the UK.

If you have come across a product described as tirzepatide 80 mg, treat it as a serious red flag. You can report suspect sellers directly at the MHRA's Yellow Card scheme, which accepts reports on both side effects and suspect medicines.

For a clear picture of how the licensed titration schedule is structured, the tirzepatide dosing guide walks through each step in plain terms.

What are the six UK-licensed tirzepatide strengths and how does titration work?

Treatment starts at 2.5 mg, a dose whose job is to let your body adjust to the medicine rather than to produce significant weight loss. After roughly four weeks, a prescriber typically reviews tolerability and, if things are going well, moves the dose up. Each subsequent step (5, 7.5, 10, 12.5 and finally 15 mg) follows the same four-week rhythm, though the pace is always guided by how the patient is getting on.

This graduated approach exists because tirzepatide activates both the GIP and GLP-1 receptors involved in appetite regulation and gastric emptying, and the gastrointestinal system needs time to settle as the dose rises. Rushing the titration tends to increase side effects without meaningfully improving outcomes. The prescriber's job is to find the highest dose you tolerate well, not to reach 15 mg as a target in its own right.

Some people find that 5 mg is where they stay long term; others move through the full ladder. What matters is clinical response and tolerability, assessed at every step. For further context on what the lower end of the schedule looks like in practice, the page on 1 mg tirzepatide queries explains why sub-2.5 mg strengths are not part of the licensed range either.

Storing the pen correctly matters throughout: keep it in the fridge door between 2 and 8°C, and check the Patient Information Leaflet for the exact window if you need to take it out temporarily, that detail varies and the leaflet is the authority.

Does the 15 mg strength come in a single-dose pen like the 5 mg?

Every Mounjaro KwikPen, regardless of strength, delivers four weekly doses. So the pen you collect or receive contains enough medicine for one month of treatment at the labelled strength. The pen label shows the per-injection dose (15 mg in the case of the highest strength) not a total content figure. A prescriber at a regulated service like ours confirms the appropriate strength at the point of prescribing and at every clinical review before a repeat.

The SURMOUNT-1 trial, published in the New England Journal of Medicine, found that participants reaching 15 mg saw an average body-weight reduction of around 20 to 21 per cent over 72 weeks, among the strongest results in weight-management medicine to date. Those figures come from a controlled clinical environment; a prescriber considers your individual health picture rather than applying trial averages directly. NICE's appraisal of tirzepatide (TA1026) reviewed this evidence in reaching its recommendations about the medicine's place in treatment.

Pricing has shifted since Eli Lilly revised its UK list price in September 2025; a factual summary of what that change meant for private costs is on the Mounjaro price increase page. Understanding what a legitimate private prescription actually covers (consultation, clinical review, dispensing and delivery) matters as much as the headline figure.

What should you do if you were looking for a higher dose?

If you reached this page hoping tirzepatide went higher than 15 mg, you are not alone. People who have found the medicine effective often wonder whether more would do more. The clinical reality is that the licensed ceiling is set by the evidence: the doses studied and approved are the doses shown to be both effective and acceptably safe in trials involving thousands of adults.

If you feel your current dose is not working as expected, the right route is a conversation with your prescriber rather than seeking an unlicensed strength. For people already on treatment through another provider, our prescribers at our clinical team are experienced in reviewing transfer patients and can assess whether a change in dose, medicine or approach makes clinical sense. Those just starting out can find a full overview of the treatment options available at our weight-loss treatments page.

Equally, if someone has offered you a higher-strength product through an informal channel, the MHRA's public guidance on GLP-1 medicines is clear: products sold without a prescription, particularly those with dose labelling that does not match any licensed formulation, carry real risks. The tirzepatide supply chain in the UK runs through licensed pharmacies dispensing against a valid prescription. That is the only route that comes with any meaningful safety guarantee.